Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

Leena Gandhi, MD, PhD
Published: Thursday, Oct 26, 2017



Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

Gandhi says that there is clear-cut evidence of the superiority of alectinib over crizotinib (Xalkori). Results from the J-ALEX and ALEX trials showed improved long-term outcomes systemically with alectinib, and in the central nervous system (CNS), as well.
 


Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

Gandhi says that there is clear-cut evidence of the superiority of alectinib over crizotinib (Xalkori). Results from the J-ALEX and ALEX trials showed improved long-term outcomes systemically with alectinib, and in the central nervous system (CNS), as well.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x